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Despite  the  substantial  advances  obtained  in  the  treatment  of localized  malignancies,  metastatic  disease
still  lacks  effective  treatment  and  remains  the  primary  cause  of cancer  mortality,  including  in breast
cancer.  Thus,  in order  to improve  the  survival  of  cancer  patients  it  is  necessary  to  effectively  improve
prevention  or treatment  of metastasis.  To  achieve  this  goal,  complementary  strategies  can  be  envisaged:
the  ﬁrst  one  is  the  eradication  of established  metastases  by  adding  novel  modalities  to current  treatments,
such  as  immunotherapy  or  targeted  therapies.  A second  one  is  to prevent  tumor  cell  dissemination  to sec-
ondary  organs  by  targeting  speciﬁc  steps  governing  the  metastatic  cascade  and  organ-speciﬁc  tropism.  A
third  one  is  to block  the  colonization  of secondary  organs  and  subsequent  cancer  cell  growth  by  imping-
ing  on the  ability  of disseminated  cancer  cells to adapt  to  the  novel  microenvironment.  To  obtain  optimal
results  it might  be  necessary  to  combine  these  strategies.  The  development  of therapeutic  approaches
aimed  at preventing  dissemination  and  organ  colonization  requires  a deeper  understanding  of the  speciﬁc
genetic  events  occurring  in cancer  cells  and  of the  host  responses  that  co-operate  to promote  metastasis
formation.  Recent  developments  in  the  ﬁeld  disclosed  novel  mechanisms  of metastasis.  In  particular  the
crosstalk  between  disseminated  cancer  cells  and  the  host  microenvironment  is emerging  as a critical
determinant  of  metastasis.  The  identiﬁcation  of tissue-speciﬁc  signals  involved  in  metastatic  progres-
sion  will open  the  way  to new  therapeutic  strategies.  Here,  we  will review  recent  progress  in the  ﬁeld,
with  particular  emphasis  on the  mechanisms  of organ  speciﬁc  dissemination  and  colonization  of breast
cancer.
1. Introduction
Despite recent major advances in the understanding of the
mechanisms of breast cancer progression and in the development
of novel therapeutic modalities, breast cancer remains the sec-
ond leading cause of mortality among women. Mortality is almost
invariably due to  metastasis. For example, between 25% and 50%
of patients diagnosed with breast cancer will eventually develop
deadly metastases, often decades after the time of diagnosis and
removal of the primary tumor. The prognosis for patients with
metastatic breast cancer is  generally unfavorable, with an aver-
age 5-year survival rate of only about 25% [1,2]. The different
histological subtypes of breast cancer (e.g.  ductal, lobular, basal-
like) and molecular marker expression (e.g.  estrogen receptor,
ER; progesterone receptor, PR; human epidermal growth factor
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receptor 2,  HER2) have strong prognostic and predictive values. For
example, triple negative breast cancers (i.e.  ER-, PR-,  HER2-
negative) are associated with a  signiﬁcantly increased risk of
progression and metastasis formation. In spite of intense clini-
cal research efforts, only limited advances have been obtained in
the  management of breast cancer metastases. Therapeutic options
are mainly based on the systemic administration of cytotoxic
chemotherapy, or radiotherapy and surgery for isolated lesions, but
the long-term impact on survival is limited [3]. Metastatic disease
still remains the most critical condition limiting patient survival,
and the development of effective treatment against metastatic
cancers, including breast cancer, is among the most outstanding
challenge in  current experimental and clinical cancer research.
Although surgery, chemotherapy and radiation therapy can control
primary tumor growth, they are not very effective in prevent-
ing relapses. It  has been recently demonstrated that targeted
immunotherapy against tumor tissue can generate an adaptive
immune response mediated by cytotoxic T  cells that further tar-
gets distant metastatic sites [4]. The process of metastasis has been
traditionally viewed as a multi-step sequential cascade of events
starting from local invasion at site of primary tumor, progres-
sion toward hematogenic or  lymphogenic spreading, colonization
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and outgrowth at distant sites [5]. Metastases are  themselves
often source of further dissemination to  additional tissues. Recent
experimental evidence revealed that cancer cells recirculate from
metastatic lesions back to  the primary tumor [6,7]. This obser-
vation, if conﬁrmed in  human cancer, would have important
implications to prediction and therapy.
One striking feature of the metastatic spread is  organ-speciﬁcity.
Recent  discoveries indicate that both molecular characteristics of
the cancer cells and of the target tissue cooperate to determine
the organotropism of metastasis observed for many tumors [8,9].
The dissection of the mechanisms by  which different tumor types
spread to speciﬁc organs and the identiﬁcation of the molecules
and pathways involved is one of the emerging topic of investiga-
tion in current cancer research [10]. Unraveling these molecules
and pathways might open the way for unprecedented therapeu-
tic opportunities to translate into the clinic. Here we will review
some of the emerging concepts and recent ﬁndings in  breast can-
cer metastasis, and discuss their biological and clinical relevance as
well as some of the remaining and emerging open questions.
2.  Spatial–temporal models of tumor cell dissemination
To develop clinically detectable metastases, cancer cells must
complete chronologically and functionally well-deﬁned and inter-
related steps, globally referred to as the metastatic cascade. Tumor
cells need ﬁrst to migrate out of the primary tumor, enter into
the bloodstream (or lymphatic vessels) and to  seed at distant, sec-
ondary sites [11,12]. The disseminated tumor cells then need to
evade the host immune responses and to  adapt to the local “foreign”
microenvironment in order to  survive, proliferate and successfully
form secondary tumors [13]. The basic events of the metastatic
cascade, such as initial invasion and circulation in the blood are
shared by different tumor types, while other ones, in particular
the colonization of speciﬁc organs and secondary growth, are  spe-
ciﬁc for distinct tumor types and different target organs [8–10]. The
metastatic process itself is  believed to  be highly inefﬁcient, since
only a small fraction of cancer cells entering the circulation will suc-
cessfully generate secondary tumors. This low metastatic efﬁciency
is considered to be the result of tumor cell death in  the blood cir-
culation, caused by the exposure to  shear stress and hemodynamic
forces and induction of anoikis due to lack of adhesion to matrix
and to immune attack by cytotoxic effector cells [14,15].
Traditionally, it is considered that metastatic dissemination
occurs late during tumor progression, at a time when the primary
tumor has already reached a  considerable volume [16] (Fig. 1, upper
panel). Indeed, for most cancers, the primary tumor volume repre-
sents a risk factor for progression to metastasis: the greater the
volume, the higher the risk. In this model, also called the linear
model of metastasis, genetic modiﬁcations progressively accumu-
late in cancer cells, whereby cells with advantageous mutations will
survive and expand in the primary tumor (clonal evolution theory
of cancer). Based on this model, cells acquiring metastatic capaci-
ties will initially form a small cell subpopulation within the primary
tumor. Accordingly, metastasis-driving mutations should be rare
in the primary tumor but frequent in the distant metastases [2,12].
The observation that metastases and their corresponding primary
tumor have similar molecular signatures has been interpreted as
evidence for this model [17–19].
Recently, however, this linear model of metastasis has been
challenged by observations suggesting that cancer cells, in  par-
ticular in breast cancer, might disseminate early during tumor
progression, i.e. at a  stage when the primary lesion is small
or possibly even at pre-malignant stages (parallel model of
metastasis) (Fig. 1, lower panel). This model implies that dissem-
inated cells evolve independently of the primary tumor [20]. In
Fig. 1. Linear and parallel models of metastasis. In the linear model of metasta-
sis  (upper panel), genetic modiﬁcations progressively accumulate in cancer cells of
the primary tumor, whereby cells with advantageous mutations will survive and
expand  through clonal evolution. Cells acquiring metastatic capacities will form a
small cell subpopulation within the primary tumor which, when disseminated, are
more effective in colonizing distant organs. In the parallel model of metastasis (lower
panel), it is proposed that cancer cells disseminate early during tumor progression,
at  a  stage when the primary lesion is  small or possibly even pre-malignant. Dissem-
inated  cells then evolve independently of the primary tumor to  form metastases.
In  breast cancer both models are supported by clinical and experimental evidences.
Metastatic  cells can disseminate through lymphatic vessels and lymph nodes ﬁrst
or directly through the blood stream. Cancer cells recirculating from metastases to
primary tumors might contribute to  bad  prognostic signatures. P, primary tumor;
M, metastasis. See Refs. [20,21,24,26].
support of this model there are observations demonstrating that
genetic alterations occurring in breast cancer cells disseminated
into the bone marrow often do not resemble to  those present in
the corresponding primary tumor [21,22]. Based on this model, the
genetic alterations in disseminated tumor cells should be more rel-
evant in predicting response to therapy in  metastatic disease than
those found in the primary tumor [23]. Tumor cells circulating in
the peripheral blood or disseminated tumor cells in  the bone mar-
row can be characterized at the single-cell level and may serve
as a  powerful tool for detection of early metastatic spreading and
determining the suitable therapy [24].
The debate on the linear versus parallel models of metastasis
raises three fundamental questions about the origin of metastatic
cancer cells, for which today we have no deﬁnitive answer: when,
where and how do metastatic cells arise in  the course of a  cancer dis-
ease? This capability may  arise very early within the primary tumor
even prior to invasion and dissemination, or it may  be acquired very
late among the already disseminated cancer cells at a time when
they need to adapt, survive and growth in the newly colonized
tissue environment [25,26].
3.  Breaking the wall
The  ﬁrst obstacle encountered by circulating tumor cells to enter
distant organs is the vascular wall, in particular the endothelial
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lining. In some organs, like the bone marrow or the liver, the
microvessels are constituted by  highly permeable sinusoids. Sinu-
soids are permissive for the physiological extravasation of blood
cells and represent weak barriers to  cancer cells. In contrast,
in most other organs endothelial cells form a  contiguous lin-
ing through which cancer cells cannot freely penetrate. An organ
with an extremely tight endothelium is the brain with its pecu-
liar blood-brain barrier. Metastasis is facilitated by blood platelets
and leukocytes, which form complexes by  L- or P-selectins with
tumor cells, thereby contributing to the arrest of such emboli
in the vasculature [27]. Enhanced expression of selectin ligands
(sLex/a, sialyl Lewis x/a glycans) is associated with metastatic
progression, and correlates with poor prognosis for patients. The
extravasation of circulating tumor cells through tight vascular beds
requires the expression of genes that will remodel the vascula-
ture to increase permeability [10,13,28]. Stroma-derived TGF-
enhances the metastatic tropism of breast cancer cells to lung by
inducing ANGPTL4 gene expression, which remodels the vascula-
ture and facilitates tumor cell extravasation [29]. Speciﬁc organ
tropism also involves the networking of cytokines and chemokines
expressed in the target tissue and interacting with their cognate
receptors expressed on tumor cells. For  example, the CXCR4 and
CCR7 receptors and their ligands CXCL12 and CCL21 respectively,
are speciﬁcally used by  breast cancer cells to arrest and migrate
into secondary organs [30,31].
4. Adapting to the new environment
The second obstacle for a disseminated cancer cells to form
growing metastases is their ability to adapt to the foreign tissue.
Physiologically, normal cells survive and proliferate within their
speciﬁc original tissue, while they are  unable to do  so outside of it
[32]. This is considered as a  critical mechanism to maintain correct
tissue identity and tropism [8,33]. In contrast, disseminated can-
cer cells can grow in  organs and tissues often very different from
their origin. For this cancer cells must acquire novel capacities, in
particular the ability to interact with the extracellular matrix and
with cells of the new microenvironment. Tumor cells establish a
bidirectional relationship with the surrounding stroma very early
during tumor progression, namely at the time of initial invasion.
Thereafter, tumor–stroma interactions actively contribute to  tumor
progression toward metastasis. Tumor cells themselves can co-opt
the colonized tissue stroma and impinge on many physiological
events favoring tumor growth and progression, such as twisting
and polarizing inﬂammation, suppressing the immune response,
promoting angiogenesis, or releasing growth, survival and motility
factors [25]. In response to tumor cells, resident stromal cells can
profoundly alter their transcriptome to express genes providing a
favorable environment for the disseminated cancer cells [34,35].
4.1.  The pre-metastatic niche
Since tissue modiﬁcations have been observed prior to  tumor
cell seeding, the concept of pre-metastatic niche has been intro-
duced. The building of an adequate pre-metastatic niche is  key
for the initial survival of the tumor cells disseminated in a  non-
compatible organ [36,37]. Kaplan et al. highlighted the role of
mobilized bone marrow-derived cells (BMDCs) in creating a suit-
able microenvironment for the metastatic colonization of the lung.
BMDCs are mobilized by factors released by the primary tumor
and are directed to the prospective sites of metastasis prior to
the arrival of the disseminated tumor cells [38,39]. These cells
express VEGFR1, CD133, CD34, and c-Kit, all markers characteristic
of hematopoietic progenitor cells (HPCs). Recruited VEGFR1+ cells
can determine the metastatic pattern characteristic of different
tumor  cell types through the secretion of speciﬁc factors. Several
molecular mechanisms involved in the formation of  the pre-
metastatic niche have been reported. The expression of  VLA-4
(41integrin) by VEGFR1+ BMDCs is  essential for their interac-
tion with ﬁbronectin deposited in  the pre-metastatic niche [38].
Once recruited, BMDCs are stimulated to  secrete matrix met-
alloproteinases (MMPs), which process the matrix and release
matrix-bound factors such as VEGF.
4.2. Molecules promoting the pre-metastatic niche
VEGFR1 signaling in BMDC and stromal cells, is  essential for the
activation of tumor-recruited BMDCs, for promoting vascular per-
meability facilitating tumor cell trans-endothelial migration, tumor
cell survival as well as epithelial-to-mesenchymal transition (EMT)
[40]. Hiratsuka et al. showed that VEGFR1 signaling is  required for
the induction of MMP-9 by endothelial cells and macrophages in
the  pre-metastatic lung [41]. The inﬂammatory chemoattractants
S100A8 and S100A9 not only act in the primary tumor microenvi-
ronment, but they also contribute to  the recruitment of CD11b+
myeloid cells to  the pre-metastatic lung and to promote tumor
cell survival through toll-like receptor TLR-4-dependent NF-B
signaling [42,43]. Erler et al. described lysyl oxidase (LOX) as a
critical molecule in the formation of the pre-metastatic niche.
LOX co-localizes with ﬁbronectin in lung basement membrane and
crosslinks collagen IV to generate a  suitable extracellular matrix
that facilitates the recruitment of CD11b+ myeloid cells and tumor
cell survival [44–46]. The importance of the extracellular matrix in
metastasis formation is  further supported by the observation that
in breast cancer tumor cells inﬁltrating the lung need to induce
stromal osteopontin expression in order to  initiate colonization
[46]. Periostin was  recently reported to  promote maintenance of
disseminated breast cancer stem cells in  the lung through the
recruitment of Wnt  ligands and induction of Wnt  signaling [47].
The extracellular matrix protein tenascin-C, which is  expressed in
normal stem cell niches is  also expressed by aggressive breast can-
cer cells forming pulmonary metastasis to promote the survival and
outgrowth of micrometastases [48]. Chemokines are further key
players in metastasis formation. For example CXCL12 (also known
as SDF1, stromal-derived factor 1) favors homing to target organs,
in particular the bone marrow, of circulating tumor cells express-
ing the cognate receptor CXCR4. The CXCL12/CXCR4 axis creates
a pre-metastatic niche in the bone for osteotropic cancers most
notably mammary, prostatic, and ovarian cancers [30,31]. Simi-
larly, CCL12/CCR7 and CCL22/CCR4 axes have been described to
promote the dissemination of breast and lung cancer cells, respec-
tively. Tumor cells expressing these chemokine receptors ﬁnd a
fertile soil within the foreign bone microenvironment due to the
secretion of their speciﬁc chemokine ligands by osteoblasts [30].
Further, osteoblasts expressing angiopoietin (Ang-1) and osteo-
pontin, are able to  attract and recruit tumor cells to  bone. Additional
studies are required to  characterize other molecular mechanisms
involved in the pre-metastatic niche formation during the coloniza-
tion and homing, in particular to  other relevant target organs, such
as brain or  liver [39,49].
5.  Organotropism of metastasis
Another  striking feature of metastasis is  that their localization
does not occur randomly but rather at selected preferred sites.
The blood circulation pattern provides only a partial explanation
for the organ-speciﬁc colonization by metastatic cancers observed
in patients [28,50]. For example, breast cancer often metastasizes
to lung, bone, liver and brain, all sites that have no immedi-
ate direct vascular connections with the mammary gland tissue.
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Rather, metastatic outgrowth requires a  proper microenvironment
where cancer cells can survive, initiate proliferation and estab-
lish a new tumor mass [9]. This notion is not new, since Stephen
Paget proposed it already in 1889 as the “seed and soil” hypothesis.
He postulated that a  successful colonization of a  secondary organ
depends on the intrinsic properties of the tumor cell itself (“seed”)
and a permissive and supportive role  of the environment (“soil”),
which co-operate to allow for survival and proliferation [13,51].
The ﬁrst experimental evidence underneath the notion that cancer
do not spread randomly was provided much later by  Isaiah Fidler
in 1973, who showed that different subpopulations of cancer cells
isolated from specimens of the same cancer patient and injected
into mice upon the same route, displayed distinctive patterns of
organ colonization [52].
Four decades of subsequent studies, revealed several molecular
aspects governing metastatic tropism and identifying mediators
of site-speciﬁc outgrowth. In particular, genes whose expression
speciﬁcally mediates metastatic colonization of breast cancer to
bone, lung and brain have been identiﬁed [53–55]. These genes
orchestrate the organ-speciﬁc pattern of metastatic spreading
by overcoming the incompatibilities between the intrinsic fea-
tures of cancer cells and the “obstacles” imposed by  the foreign
microenvironment. The metastatic tropism implies distinct adap-
tive programs determined by the organ where the metastatic
colonization and outgrowth occurs, as well as by the tissue of
origin of the metastatic cells. This double-faceted feature of the
metastatic tropism may  explain why breast carcinoma cells metas-
tasizing to different organs, such as lung, bone, liver or brain,
develop distinct genetic programs for each metastatic site. How-
ever, organ-speciﬁc mechanisms of metastasis are not universal.
Different cancers, such as breast, prostate or lung, can metasta-
size to the same target organ by  developing different molecular
programs and activate distinct signaling pathways. The pleiotropic
mechanisms of metastatic colonization can be interpreted as the
result of the pattern of accumulated genetic modiﬁcations in  the
cancer cells necessary for primary tumor growth and dissemina-
tion and the complementary modiﬁcations required for successful
survival and growth in  the foreign environment. Functions already
acquired during primary tumor growth will not need to be acquired
again during metastasis and might therefore escape detection as
pro-metastatic genes, although functionally they are (see Section
6). This multiplicity is  further complicated by  different tempo-
ral patterns of metastasis. For  example, some carcinoma such
as lung or pancreas, can form metastases in a relatively short
period of time, whereas other carcinoma, such as breast, often
take years to give rise to metastases. This suggests that some can-
cer cell types, such as pancreas, can rapidly embrace programs
to adapt to the foreign microenvironment, while other cancer
cell types, such as breast, require more time to activate pro-
grams for accomplishing the same result [34,35,56]. Considering
the genetic instability of cancer cells, and the fact that only a
small sub-population is able to overcome the multiple barriers on
the path to metastasis, it is  likely that at each step of the pro-
cess some crucial genes are modiﬁed either through mutational
events (i.e. ampliﬁcation, translocation or loss of heterozygosity),
or through transcriptional regulation, including epigenetic modiﬁ-
cations [10,35].
6.  Metastasis-promoting genes
In order to identify molecular mediators of organ-speciﬁc
metastasis, gene expression proﬁling experiments on cancer cells
with different tropism in experimental models and clinical samples
were performed. Globally, the obtained results indicate that breast
carcinoma cells acquire genetic programs and speciﬁc patterns
enabling  their subsequent preferential colonization to speciﬁc tar-
get  organs already within the primary tumor and that only a  few
additional events are  required for full metastatic capacity. Func-
tional experiments validated a number of critical genes mediating
organ-speciﬁc metastases in breast cancer [57,58]. This approach
also proved successful in  classifying genes based on their gen-
eral contribution to metastasis. Three principal categories have
been proposed: genes promoting initiation, progression or viru-
lence. Metastasis initiation genes comprise genes providing an
advantage in  tumor cell growth, escape and invasiveness at the pri-
mary tumor site, thereby facilitating intravasation into capillaries
and hematic dissemination to  distant organs. Metastasis virulence
genes provide survival advantages to disseminated tumor cells
within the newly colonized microenvironment of the secondary
organ. These genes complement the initiation genes. Metastasis
progression genes give advantages during the entire metastatic
process by affecting general steps of tumor progression, such
as tumor angiogenesis, inﬂammation, epithelial-to-mesenchymal
transition  or immune evasion. Importantly, metastasis progression
genes may  promote organotropic feature of metastasis by coupling
molecular events controlling progression of primary tumor, tissue-
speciﬁc spreading to  distant organs and survival of metastatic
cells [35,50].
Metastasis-associated signatures have been well characterized
for lung and breast cancers. The expression of these genes in  the pri-
mary tumor seems to predict organ-speciﬁc recurrence in patients
[17,59,60]. An alternative interpretation of these observations,
however, should be considered in  light of the recent observation
that in experimental tumors, metastatic cells can recirculate from
the metastatic sites back to the primary tumor site by a  mechanism
of re-seeding [6]. Such a  scenario is consistent with the existing cor-
relation between primary tumor size, high proliferation rate and
aggressive metastatic behavior leading to  a poor prognosis [7]. If
validated in  human cancer, the ability of metastatic cells to colonize
the primary tumor could explain the origin of “metastatic signa-
tures” detectable in primary tumors and at the same time weaken
the clinical predictive value of such signatures.
7. Molecules mediating organ-speciﬁc metastasis
In this paragraph we will brieﬂy review molecular mechanisms
of organ-speciﬁc metastasis recently identiﬁed by gene expression
screens, gain- or loss-of-function experiments and pharmacologi-
cal interventions. Although individual genes have been associated
with organ-speciﬁc metastasis, they should be considered in a
global context, as many of them act in  concert (holistic view).
Another complication is  that one individual gene may  be respon-
sible for multiple effects while different genes may  contribute to
the acquisition of one particular feature. These pleiotropic and
redundant effects exerted by a  complex, dynamic and interactive
network of multiple genes might explain the width and complex-
ity of mechanisms underlying tissue-tropism of metastatic cells.
This complexity and pleiotropism is reﬂected in the multiple, non-
identical, yet interchangeable prognostic signatures reported in
breast cancer [2,59,61]. Initial evidence for the existence of genes
driving organ-speciﬁc metastasis came from the identiﬁcation of  a
70-gene poor prognosis signature associated with the propensity to
form distant metastases, through supervised clustering of a  cohort
of primary breast cancers (Rosetta-type poor prognosis signature)
[62–65].
Subsequent experimental work mainly done by the Massagué’s
laboratory, described gene expression signatures associated with
organ-speciﬁc metastasis in experimental models, which were
validated in  human breast cancer. Microarray-based comparison
of the parental cancer cell lines to  the organotropic metastatic
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Fig. 2. Gene mediating organ speciﬁc breast cancer metastasis. Breast cancer genes
promoting organ-speciﬁc metastasis to bone, lung and brain have been identi-
ﬁed.  They include proinﬂammatory molecules and chemokines/receptors (e.g. COX-,
CXCL12/CXCR4), matrix-degrading and modifying enzymes (e.g. MMP1/2, LOX),
adhesion and extracellular matrix molecules (e.g. VCAM-1, TNC, OPN), transcrip-
tion  factors (e.g. ID1, KLF17), intracellular signaling proteins (e.g. SRC, NF-B),
cell  communication proteins (JAGGED1, CTGF). Some genes promote seeding (e.g.
ST6GALNAC5, AGPTL4), while others promote colonization (e.g. OPN, CXCR4).
This  list is meant to  grow as novel genes are continuously reported. See Refs.
[33,48,53,74].
lines identiﬁed genes mediating metastasis to bone, lung and brain
[53–55] (Fig. 2).
7.1.  Genes mediating metastasis to lungs and bones
The bone metastasis signature revealed 43 over-expressed and
59 under-expressed genes in bone metastatic BoM1 cell line, iso-
lated after one round of in vivo selection by  intra-cardiac injection
of the parental breast cancer cell line MDA-MB-231 [53]. Simi-
larly, a lung metastasis signature consisting of 48 over-expressed
and 47 under-expressed genes was identiﬁed from the lung-
metastatic LM2  cell line, isolated after two rounds of in vivo
selection by intra-vein injection of the same parental breast can-
cer cell line and recovery from the lung [54]. Among these genes
only six were present in  both signatures. Several lung metasta-
sis genes were strongly associated with tumor invasiveness and
aggressiveness, rather than functions in  lung tissue, while bone
metastasis-promoting genes were more related to bone microen-
vironment [58]. Bone metastatic cells take advantage from the
physiological  cycle of bone remodeling, mediated by  genes such
as IL-11, PTHrP and OPN, to  survive and grow within the bone
microenvironment.
7.2. Genes mediating metastasis to the brain
Using a similar approach, the same group further described a
brain metastasis signature. In this model, breast cancer cells were
injected directly into the arterial circulation, and then isolated from
the brain. After two  rounds of in vivo selection a  brain metastatic
line (BrM2) was obtained. The gene expression proﬁle of the brain
metastatic line identiﬁed 243 genes that were further analyzed for
their association with brain relapse in independent clinical breast
cancer data sets. The resulting 17-gene brain metastasis signature
clinically correlated with basal-type ER-negative breast cancer sub-
type. One-third of the brain metastasis signature genes overlapped
with genes of the lung metastasis signature. While these com-
mon genes cannot explain the speciﬁc and unique brain metastatic
tropism they reveal that the brain metastasis signature is very dif-
ferent from the bone metastasis signature. The ST6GALNAC5 gene
was found to be exclusively expressed in the brain-metastatic line
and up-regulated in human brain metastasis samples. Functional
validation experiments demonstrated a role in promoting brain
metastasis by facilitating passage through the blood–brain barrier
[55]. The signiﬁcant overlap found between the lung and brain,
but not  bone metastasis signatures might be due to the functional
similarity of the vasculature in  lungs and brain. While the microvas-
culature in bone and liver is fenestrated, the one in lungs and brain
is constituted by a continuous layer of endothelial cells with well-
developed tight junctions. Therefore lung and brain metastatic cells
need to overcome thigh vascular barriers to colonize their target
organs. This notion is  supported by the observation that some of
the overlapping genes, such as COX2, ANGPTL4, LTBP1 and EGFR-
ligands are functionally involved in  controlling endothelial cell
adhesion and vascular permeability.
7.3. Clinical signiﬁcance and limitations
These signatures displayed an additional clinical value when
applied to  the 70-gene Rosetta-type poor prognosis signature and
several independent cohorts of breast cancer patients. They appear
to be robust, since the clinical correlation of metastasis-associated
genes with the metastatic outcome and tropism was  consistent
across different patient cohorts analyzed and different microarray
platforms [10,50,61]. From a  mechanistic perspective, these sig-
natures already contributed to make important advances in  the
characterization of novel molecular mediators of organ-speciﬁc
metastasis. By coupling functional genomic approaches with more
appropriate clinically-relevant metastasis models, it will be possi-
ble in  the future to further improve our knowledge of  metastasis
organotropism with the aim of translating this knowledge into an
improved clinical management of breast cancer metastasis [57].
It is important to keep in mind, however, that these signatures
were obtained using experimental metastasis assays by  directly
inoculating cells into the circulation (i.e.  intra-cardiac injections for
bone and brain and lateral tail vein injections for lung metastases),
thereby mimicking only the latter steps of metastatic process.
Interestingly when these metastatic cell populations were ortho-
topically implanted in mouse mammary gland, the bone metastatic
line grew with a  comparable rate as the parental cell line, while the
lung metastatic line showed a  more rapid growth. This observation
indicates that some organ-speciﬁc metastatic genes have already
effects on primary tumor growth, supporting the notion that genes
promoting primary tumor growth may  also be relevant to  metas-
tasis formation. Future models should try to mimic spontaneous
metastasis formation from primary tumors (see below).
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Fig. 3. Outstanding questions in breast cancer metastasis research. Innovative research approaches have provided important advances towards the identiﬁcation of mech-
anisms of metastasis and associated molecules. A number of old questions have remained, however, and some new ones are emerging. Answering these questions might
give some explanations why  current therapies have limited impact on controlling metastatic disease and might open new avenues in designing more effective therapeutic
approaches.
8. Metastatic dormancy
The  observation that the vast majority of the metastases become
evident only after removal or treatment of the primary tumor,
indicates that disseminated cancer cells must be able to  remain
viable and silent for a  long period of time, a  phenomenon referred
to as tumor dormancy, although “metastatic dormancy” would be
more appropriate [66,67]. For example, metastases of ER-positive
breast cancer, of prostate cancer or  melanoma might become clin-
ically apparent only years or decades after the surgical resection
of even small primary lesions. The fact that relapses occur so
late implies that these tumor cells are not fully capable to give
rise to a secondary tumor at the moment of their seeding, yet
they remain viable and progressively acquire this capacity through
additional genetic and epigenetic modiﬁcations or  cues from the
tumor microenvironment [14,68]. This state of dormancy sug-
gests that disseminated tumor cells might have low proliferative
and low metabolic activities. This could represent a  major obsta-
cle limiting the efﬁciency of adjuvant chemotherapies, which are
rather aimed at targeting highly active and proliferating cells.
This might be the reason why adjuvant treatments often fail to
eradicate dormant metastases [67,69]. However, prolonged dor-
mancy is not seen in all cancer. For example, rapidly growing
cancers, such as lung carcinoma and pancreatic adenocarcinoma
display a quick metastatic evolution in secondary organs. These
tumors rapidly acquire and develop genetic programs that con-
fer colonization competence over a  short period of time (weeks
to months) following treatment of the primary tumor. Other can-
cers show mixed behaviors. For example, colorectal cancer might
take decades for the transition from hyperplasia to dysplasia (ade-
noma), to in situ carcinoma and to invasive carcinoma, while it
can rapidly progress to form metastases upon initiation of invasion
[67,70]. This variability in  the kinetic of metastatic progression is
likely to reﬂect the great heterogeneity and complexity of the cel-
lular and genetic events controlling metastasis among the different
tumor types. Understanding metastatic dormancy is  likely to open
the way to novel approaches to the long-term control of cancer
progression.
9. Concluding remarks and outlooks
Despite the successful therapeutic management of primary
breast cancer, a signiﬁcant fraction of the patients develop
metastases, sooner or later. Breast cancer relapse is associated with
a high rate of mortality. Since in  patients the early steps in the
metastasis process cannot be effectively targeted (as they have
already occurred when metastases are detected), the latter steps
of colonization and outgrowth at distant sites appear most suit-
able for therapeutic interventions. The development of strategies
to effectively treat metastasis will beneﬁt from the mechanistic
understanding of metastasis organotropism as the results from the
crosstalk between intrinsic properties of breast carcinoma cells
and speciﬁc features of the colonized organ microenvironment.
The recent reports that tenascin-C [71] and periostin [47] promote
breast cancer stem cell survival in  the lung and that VCAM-1 stim-
ulates breast cancer cells survival and outgrowth in  the lung and
bone are important steps in  this direction [48,72].
9.1. New models
The  experimental models of metastasis obtained by
xenografting human breast cancer metastatic cell lines into
immune-compromised mice through direct inoculation into the
bloodstream emerged as valuable tools that allowed the identi-
ﬁcation of organ-speciﬁc metastatic signatures. However, these
models are  limited, since they only recapitulate the latter steps
of a  long, multistep process and bypass the need of a  primary
tumor. In view of the priming role of the primary tumor in
metastasis formation (i.e.  pre-metastatic niche model) and of  the
species-speciﬁcity of several cytokines involved in  the cross-talk
between cancer cells and microenvironment, it is  therefore cru-
cial to develop more clinically relevant models or spontaneous
organ speciﬁc metastasis in immune-competent mice, based on
orthotopic tumor cell implantation or spontaneous (transgenic)
tumor formation. This will be relevant to the preclinical validation
of candidate therapeutic targets. Orthotopic and spontaneous
models of metastasis are expected to better fulﬁll the criteria
necessary for developing anti-metastatic treatments eventually
effective in patients, by disclosing failures or adverse side effects
before reaching clinical testing [73]. We  have recently developed
an orthotopic and syngeneic model of breast cancer metastasis to
the brain that allowed the identiﬁcation of previously unsuspected
genes conferring brain metastatic tropism to  breast cancer cells
(G. Lorusso, in preparation). Furthermore, it will be  necessary to
validate target genes identiﬁed in  experimental models by ana-
lyzing their expression in public databases through bioinformatic
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approaches, as well as by  direct validation of target genes on his-
tological sections of clinical samples, early on during the discovery
process [65]. The identiﬁcation of patient subgroups co-expressing
sets of genes that predispose to metastasis might eventually have
a prognostic and predictive therapeutic value in the selection of
the appropriate patient population to  include in  clinical trials of
novel anti-metastatic agents.
9.2. More questions
Recently, innovative approaches, such the whole-genome
sequencing of primary human tumors and matched metastases,
coupled with proteomic-based approaches, have provided impor-
tant advances in the identiﬁcation of the molecular drivers of
metastasis [57]. These approaches, together with relevant exper-
imental models of disease progression, will contribute to  improve
our understanding of mechanisms of breast cancer metastasis. In
spite of these advances, some outstanding questions in the ﬁeld
have still no answers. They include (Fig. 3): When, where, and how
do metastatic cells arise within the primary tumor? Can we iden-
tify metastasis-forming circulating tumor cells among the whole
population or circulating tumor cells and thereby estimate the risk
of progression? Can we  use circulating tumor cells to select the
most effective therapy to prevent or treat metastases? What are the
critical organ-speciﬁc determinants controlling colonization and
growth, and can we impinge on them for therapeutic purposes?
Are there organ-speciﬁc cues inﬂuencing response to therapy?
Does the microenvironment control initiation and termination
of metastatic dormancy? Do recirculating tumor cells contribute
to promote primary tumor growth (and the bad prognostic sig-
natures)? Answering these questions will by key to understand
why current therapies have such a  limited impact on controlling
metastatic disease and will be instrumental in designing more
effective drugs and therapeutic approaches.
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